Lowers the risk of periprocedural myocardial infarction (MI), repeat coronary…. Sold as Kengreal. Every FDA application for this active ingredient: 1 branded and 2 generic.
As of Nov 13, 2026, FDA lists 3 applications for Cangrelor (sold as Kengreal), first approved Jun 22, 2015, with 0 new uses approved and 0 published complete response letters.
| Cangrelor As Treatment for Cardiac Surgery Associated With Heparin Induced ThrombocytopeniaHeparin-induced Thrombocytopenia · Société Française d'Anesthésie et de Réanimation | — | Not yet recruiting | Sep 14, 2026 |
| Minimally Invasive Coronary Artery Bypass Supported by CangrelorCoronary Artery Disease, Antiplatelet Therapy · Cardiocentro Ticino | — | Recruiting | Apr 7, 2026 |
| The Bridging Antiplatelet Therapy With Cangrelor 2 StudyCoronary Arterial Disease (CAD) · University of Florida | Phase 4 | Recruiting | Nov 10, 2025 |
| Cangrelor on Top of anticoagUlation in Patients With myocaRdial Infarction-related Cardiogenic Shock/Cardiac Arrest receiVIng VA-ECMOCardiogenic Shock, Extracorporeal Membrane Oxygenation Complication · IRCCS San Raffaele | Phase 2 | Recruiting | Jan 27, 2025 |
| Effects of Cangrelor on MIcRovAscular Disfunction During Elective Percutaneous CORonary InterventionCoronary Artery Disease · Federico II University | Phase 4 | Recruiting | Oct 18, 2023 |
| Proximal Internal Carotid Artery Acute Stroke Secondary to Tandem or Local Occlusion Thrombectomy TrialAcute Ischemic Stroke · Mercy Health Ohio | Phase 3 | Recruiting | Nov 10, 2022 |
| Parenteral Antiplatelet Agents in Real-world Spanish PCI PatientsIschemic Heart Disease, Acute Coronary Syndrome · Fundación EPIC | — | Active, not recruiting | Jan 14, 2022 |
Applications, approvals and products come from FDA's Drugs@FDA data files, refreshed weekly, grouped by active ingredient as FDA spells it. Complete response letters are FDA's published letters. Medicare spending is CMS's Part D and Part B dashboard, matched to this ingredient by generic name; shortages are FDA's shortage list, matched by application number; clinical trials are ClinicalTrials.gov studies naming the ingredient as an intervention, refreshed daily; safety programs are FDA's REMS list, matched by application number or, for shared programs, by ingredient. Drugs@FDA
